Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Schott Pharma AG KGaA's operating assets for the quarter that ended in Mar. 2026 was €1,577.7 Mil. Schott Pharma AG KGaA's operating liabilities for the quarter that ended in Mar. 2026 was €665.9 Mil. Schott Pharma AG KGaA's Total Assets for the quarter that ended in Dec. 2025 was €1,627.8 Mil. Therefore, Schott Pharma AG KGaA's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.56.
Schott Pharma AG KGaA Scaled Net Operating Assets Related Terms
Schott Pharma AG KGaA Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Scaled Net Operating Assets Chart
MIL:1SXP vs ISRG, BDX, MDLN: Scaled Net Operating Assets Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.56 mean?
Schott Pharma AG KGaA (MIL:1SXP) has a Scaled Net Operating Assets of 0.56 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's Scaled Net Operating Assets too high?
Schott Pharma AG KGaA's current Scaled Net Operating Assets is 0.56. Overall, Schott Pharma AG KGaA has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Scaled Net Operating Assets compare to ISRG and BDX?
Schott Pharma AG KGaA's Scaled Net Operating Assets of 0.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current Scaled Net Operating Assets is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Significantly Undervalued. The stock's GF Value™ is €27.95, compared to a current price of €17.34 — trading 38% below its estimated fair value. The current Scaled Net Operating Assets is 0.56. Schott Pharma AG KGaA's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current Scaled Net Operating Assets is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €17.34 is trading 38% below its estimated GF Value™ of €27.95.
GuruFocus considers Schott Pharma AG KGaA to be Significantly Undervalued.
Key valuation signals for MIL:1SXP:
Scaled Net Operating Assets: 0.56
GF Value™: €27.95 vs. price of €17.34 (38% below fair value)
No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
59GF Score
Get the complete analysis for MIL:1SXP
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1SXP has been successfully added to your 
